Evidence map›Paper›PMID 35778290›Full record

ArticlePathology2022

Proficiency testing for SARS-CoV-2 whole genome sequencing.

Katherine A Lau, Kristy Horan, Anders Gonçalves da Silva, Alexa Kaufer, Torsten Theis, Susan A Ballard, William D Rawlinson

Abstract read
In one paragraph

Article in Pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Katherine A LauRCPAQAP Biosecurity, St Leonards, NSW, Australia. Electronic address: katherine.lau@rcpaqap.com.au.
Kristy HoranCommunicable Diseases Genomics Network (CDGN), Public Health Laboratory Network (PHLN), Sydney, NSW, Australia; Microbiological Diagnostic Unit Public Health Laboratory (MDU PHL), The University of Melbourne at The Peter Doherty Institute for Immunity and Infection, Melbourne, Vic, Australia.
Anders Gonçalves da SilvaCommunicable Diseases Genomics Network (CDGN), Public Health Laboratory Network (PHLN), Sydney, NSW, Australia; Microbiological Diagnostic Unit Public Health Laboratory (MDU PHL), The University of Melbourne at The Peter Doherty Institute for Immunity and Infection, Melbourne, Vic, Australia.
Alexa KauferRCPAQAP Biosecurity, St Leonards, NSW, Australia.
Torsten TheisRCPAQAP Biosecurity, St Leonards, NSW, Australia.
Susan A BallardCommunicable Diseases Genomics Network (CDGN), Public Health Laboratory Network (PHLN), Sydney, NSW, Australia; Microbiological Diagnostic Unit Public Health Laboratory (MDU PHL), The University of Melbourne at The Peter Doherty Institute for Immunity and Infection, Melbourne, Vic, Australia.
William D RawlinsonSerology and Virology Division (SAViD) SEALS Microbiology, NSW Health Pathology, SOMS, BABS, Women's and Children's, University of NSW, Sydney, NSW, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extensive studies and analyses into the molecular features of severe acute respiratory syndrome related coronavirus 2 (SARS-CoV-2) have enhanced the surveillance and investigation of its clusters and transmission worldwide. The whole genome sequencing (WGS) approach is crucial in identifying the source of infection and transmission routes by monitoring the emergence of variants over time and through communities. Varying SARS-CoV-2 genomics capacity and capability levels have been established in public health laboratories across different Australian states and territories. Therefore, laboratories performing SARS-CoV-2 WGS for public health purposes are recommended to participate in an external proficiency testing program (PTP). This study describes the development of a SARS-CoV-2 WGS PTP. The PTP assessed the performance of laboratories while providing valuable insight into the current state of SARS-CoV-2 genomics in public health across Australia. Part 1 of the PTP contained eight simulated SARS-CoV-2 positive and negative specimens to assess laboratories' wet and dry laboratory capacity. Part 2 involved the analysis of a genomic dataset that consisted of a multi-FASTA file of 70 consensus genomes of SARS-CoV-2. Participating laboratories were required to (1) submit raw data for independent bioinformatics analysis, (2) analyse the data with their processes, and (3) answer relevant questions about the data. The performance of the laboratories was commendable, despite some variation in the reported results due to the different sequencing and bioinformatics approaches used by laboratories. The overall outcome is positive and demonstrates the critical role of the PTP in supporting the implementation and validation of SARS-CoV-2 WGS processes. The data derived from this PTP will contribute to the development of SARS-CoV-2 bioinformatic quality control (QC) and performance benchmarking for accreditation.

Indexed as

COVID-19SARS-CoV-2AustraliaHumansLaboratory Proficiency TestingWhole Genome Sequencingbioinformatics analysisproficiency testingSARS-CoV-2whole genome sequencing

Identifiers

PMID35778290
PMCPMC9239710

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.